iWear oxygen presbyopia
CooperVision, Inc. · Decision date Aug 20, 2025
What did the FDA approve?
FDA records P080011/S186 as a supplement to PMA P080011, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 20, 2025.
FDA approval order statement
approval for labeling change to add new private label brand name, iWear oxygen presbyopia. The name iWear oxygen presbyopia is intended for the multifocal lens design
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Ophthalmic
- Decision date
- Aug 20, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P080011/S186
- Regulatory pathway
- PMA supplement
- Applicant
- CooperVision, Inc.
- Product code
- LPM
- Decision code
- APPR
- Decision date
- Aug 20, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Applicant
- CooperVision, Inc.
- Product code
- LPM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P080011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P080011 · Original PMA
BIOFINITY (COMFILCON A)
P080011/S186 received
Application receipt date recorded by FDA.
P080011/S180 · Related supplement
up&up Monthly Performance, up&up Monthly Performance XR, up&up Monthly Performance for Astigmatism, up&up Monthly Perfor
P080011/S184 · Related supplement
up&up Monthly Performance +
P080011/S186 · FDA decision
Normal 180 Day Track No User Fee
P080011/S192 · Related supplement
Biofinity Toric Multifocal and Biofinity XR Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S191 · Related supplement
Sofmed breathables XW NEXT
P080011/S193 · Related supplement
Biofinity XR Toric and Biofinity Toric Multifocal (Comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S194 · Related supplement
comfilcon A Soft (Hydrophilic) Contact Lenses for daily wear
P080011/S195 · Related supplement
Biofmity XR Torie (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S196 · Related supplement
Biofinity Sphere and Biofinity Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S197 · Related supplement
Biofinity Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S198 · Related supplement
Biofinity Toric Multifocal (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S199 · Related supplement
Biofinity Sphere, Biofinity XR Sphere, Biofinity Energys, Biofinity Toric, Biofinity XR Toric, Biofinity Multifocal; Bio
P080011/S200 · Related supplement
Biofinity Sphere, Biofinity XR Sphere, Biofinity Energys, Biofinity Toric, Biofinity XR Toric, Biofinity Multifocal; Bio
P080011/S201 · Related supplement
Biofinity Sphere; Biofinity XR Sphere; Biofinity Energys; Biofinity Toric; Biofinity XR Toric; Biofinity Multifocal
P080011/S202 · Related supplement
comflicon A Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S203 · Related supplement
comfilcon A Soft (Hydrophilic) Contact Lenses for Extended Wear
P080011/S204 · Related supplement
BIOFINITY (COMFILCON A)
Timeline entries are records held by MedtechLedger for P080011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BIOFINITY (COMFILCON A)P080011 | CooperVision, Inc. | PMA approval | Nov 19, 2008 | FDA |
| CooperVision, Inc. | PMA supplement | Jul 23, 2025 | FDA | |
up&up Monthly Performance +P080011/S184 | CooperVision, Inc. | PMA supplement | Aug 20, 2025 | FDA |
| CooperVision, Inc. | PMA supplement | Sep 22, 2025 | FDA | |
Sofmed breathables XW NEXTP080011/S191 | CooperVision, Inc. | PMA supplement | Dec 5, 2025 | FDA |
| CooperVision, Inc. | PMA supplement | Dec 11, 2025 | FDA | |
| CooperVision, Inc. | PMA supplement | Jan 7, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Feb 2, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Feb 10, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Mar 4, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Mar 4, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Mar 18, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Apr 9, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | May 4, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Jun 16, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Jul 7, 2026 | FDA | |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
| Alcon Laboratories, Inc. | PMA supplement | May 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CooperVision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6101 Bollinger Canyon Rd., Suite 500, San Ramon, CA, 94583
Sources and methodology
- Original FDA record: P080011/S186
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






